REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
Rhea-AI Summary
REGENXBIO (Nasdaq: RGNX) reported Q2 2026 revenues of $108.0 million, up sharply from $21.4 million a year earlier, driven mainly by a $100 million AbbVie milestone tied to first dosing in the Phase IIb/III NAAVIGATE diabetic retinopathy study. Net income was $22.7 million, or $0.43 per share, versus a $70.9 million loss in Q2 2025.
Cash, cash equivalents and marketable securities were $105.5 million on June 30, 2026; including July’s $100 million milestone and roughly $108 million in equity offering proceeds, pro forma cash exceeded $313 million, extending the cash runway into Q4 2027. Operationally, the Phase III AFFINITY DUCHENNE trial for RGX-202 met its primary endpoint with high statistical significance, RGX-202’s confirmatory study fully enrolled ahead of schedule, and the FDA confirmed no additional studies are needed for RGX-121’s planned Q3 2026 BLA resubmission. Topline data for surabgene lomparvovec (ABBV-RGX-314) wet AMD pivotal trials are expected in Q4 2026, with multiple BLA submissions targeted between 2026 and 2027.
Positive
- Q2 2026 revenue $108.0M, up from $21.4M in Q2 2025
- $22.7M Q2 2026 net income vs. $70.9M net loss in Q2 2025
- $100M AbbVie milestone from first patient dosed in NAAVIGATE
- ~$108M estimated net proceeds from July 2026 equity offering
- Pro forma cash ~$313M as of June 30, 2026 including July inflows
- AFFINITY DUCHENNE Phase III met primary endpoint with p<0.0001
- FDA requires no additional RGX-121 studies for Q3 2026 BLA resubmission
- Cash runway expected to extend into Q4 2027
Negative
- Cash and securities fell to $105.5M from $240.9M since Dec. 31, 2025
- ZOLGENSMA royalty revenue declined by $16.7M YoY in Q2 2026
- G&A expenses rose to $21.6M from $19.9M in Q2 2025
- Royalty monetization liabilities totaled $181.5M at June 30, 2026
- Interest expense was $7.8M in Q2 2026 and $16.5M for 1H 2026
News Explained
The financing creates a dilution mechanism for existing holders: common shares were issued, while pre-funded warrants can convert into additional shares.
The July underwritten public offering included common stock and pre-funded warrants; the balance sheet reported 54,164 thousand common shares outstanding on
A pre-funded warrant converts into shares when exercised, while issuing additional shares increases the total share count and reduces an existing holder’s percentage ownership absent offsetting changes.
Market Reaction – RGNX
Following this news, RGNX has gained 7.81%, reflecting a notable positive market reaction. Our momentum scanner has triggered 7 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $11.32.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 earnings report | Positive | -37.8% | Positive RGX-202 data accompanied revenue decline, net loss, and reduced cash runway. |
| Mar 05 | Q4 earnings report | Negative | -4.6% | Annual loss and regulatory setbacks accompanied pipeline milestone updates and lower cash burn. |
| Nov 06 | Q3 earnings report | Negative | -3.8% | Quarterly loss and ongoing development requirements accompanied multiple future clinical milestones. |
| Aug 07 | Q2 earnings report | Negative | -4.0% | Quarterly loss and development spending accompanied pipeline advancement and financing activity. |
| May 12 | Q1 earnings report | Positive | +2.6% | Revenue growth and net income accompanied pipeline progress and partnership payments. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific history showed four negative 24-hour reactions across five earnings reports, including a sharp decline after positive clinical progress.
Key Terms
accelerated approval regulatory
microdystrophin medical
anti-vegf medical
randomized-controlled study technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027
- Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalyst
- Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCENT ®**, expected in Q4 2026
- Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing
- Reaffirmed path forward for RGX-121 for Hunter syndrome with FDA during productive July Type A meeting; resubmission on track for Q3 2026
- Over
$200 million - Pro forma ending Q2 2026 cash, cash equivalents and marketable securities in excess of
$310 million
- Pro forma ending Q2 2026 cash, cash equivalents and marketable securities in excess of
- Webcast today at 8:00 a.m. ET
"Our second quarter was defined by strong clinical execution across our pipeline: the Phase III AFFINITY DUCHENNE® trial met its primary endpoint, we dosed the first participant in the NAAVIGATE study in diabetic retinopathy, and the FDA reaffirmed the path forward for RGX-121," said Curran Simpson, President and Chief Executive Officer of REGENXBIO. "With this progress and our strong cash runway, we are well positioned to deliver against multiple near-term, high-value catalysts, including the initiation of the RGX-202 BLA this quarter and wet AMD pivotal data in the coming months, as we advance potentially transformative gene therapies to patients."
Corporate Updates
- REGENXBIO received over
$200 million $100 million $108 million - In addition to extending the company's expected cash runway into Q4 2027, proceeds will support the initiation of the planned AFFINITY® RISE ex-
U.S . randomized-controlled trial in 1H 2027 to support global regulatory submissions for RGX-202.
PROGRAM HIGHLIGHTS AND MILESTONES
Neuromuscular Disease: RGX-202 is a potential best-in-class gene therapy for Duchenne muscular dystrophy (Duchenne). RGX-202 is designed to address the underlying cause of Duchenne by enabling targeted expression of a novel microdystrophin that is closest to naturally occurring dystrophin. The differentiated therapeutic approach behind RGX-202 includes a novel construct, with the C-Terminal domain, a proactive immune suppression regimen, and a suspension-based manufacturing process that delivers industry-leading product purity levels. RGX-202 is designed for improved muscle function, durability and positive safety outcomes and is being evaluated in the Phase I/II/III AFFINITY DUCHENNE® trial and confirmatory trial in ambulatory patients aged 1+.
- The confirmatory study of RGX-202 completed enrollment in June 2026 ahead of schedule due to strong patient demand and robust investigator interest.
- In topline pivotal data, the Phase III AFFINITY DUCHENNE® trial met its primary endpoint with high statistical significance (p<0.0001).
- RGX-202 was well-tolerated and continued to demonstrate a favorable interim safety profile and demonstrated statistically significant correlation between RGX-202 microdystrophin expression level and functional improvement at one year (NSAA, n=9).
- REGENXBIO continues to manufacture intended commercial supply of RGX-202 at its in-house Manufacturing Innovation Center.
- REGENXBIO expects to initiate AFFINITY® RISE, a new, ex-
U.S . randomized, placebo-controlled study to support RGX-202 global regulatory submissions, in 1H 2027. - The Company is on track to initiate a BLA submission in Q3 2026 under the accelerated approval pathway, supporting potential approval in 2H 2027.
Retinal Disease: Surabgene lomparvovec (sura-vec, ABBV-RGX-314), developed in collaboration with AbbVie, is potentially the first-in-class gene therapy treatment for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).
Sura-vec for the Treatment of Wet AMD (Subretinal Delivery)
- REGENXBIO expects to announce topline data with AbbVie from the ATMOSPHERE® and ASCENT® pivotal trials of sura-vec using subretinal delivery in Q4 2026.
- Global regulatory submissions are expected in 2027.
- Long-term follow-up data from the Phase I/IIa trial of sura-vec, presented at the ASRS 44th Annual Meeting in July 2026, showed stable to improved visual acuity and meaningful reductions in anti-VEGF treatment burden through five years at doses similar to those used in the pivotal trials, with the exception of one participant in Cohort 4 with polypoidal choroidal vasculopathy refractory to anti-VEGF therapy.
Sura-vec for the Treatment of DR (Suprachoroidal Delivery)
- In June 2026, REGENXBIO announced the first patient had been dosed in the Phase IIb/III NAAVIGATE study. The associated
$100 million - NAAVIGATE is a Phase IIb/III multicenter, randomized, masked, sham-controlled study enrolling subjects with non-proliferative DR (NPDR) without center-involved diabetic macular edema (CI-DME) to evaluate the safety and efficacy of a one-time, in-office administration of sura-vec.
- Long-term follow-up data from the ALTITUDE® trial, also presented at ASRS in July 2026, showed a durable safety and efficacy profile through 2.5 years at the dose being evaluated in NAAVIGATE with short-course prophylactic topical steroids.
Neurodegenerative Disease: NAVSUNLI™ (clemidsogene lanparvovec, RGX-121) is a potential first-in-class treatment for MPS II, also known as Hunter syndrome, being developed and potentially commercialized in partnership with Nippon Shinyaku.
- REGENXBIO and the FDA held a positive Type A meeting in July 2026. In the meeting, the FDA reaffirmed that no additional studies of RGX-121 are required for the BLA resubmission.
- REGENXBIO plans to resubmit the BLA in Q3 2026. The resubmission will include longer-term efficacy and safety data, including participant imaging that has been submitted to FDA and continues to be collected and analyzed as part of ongoing RGX-121 safety monitoring.
- A post-approval confirmatory study will be discussed as part of BLA review.
FINANCIAL RESULTS
Cash Position: Cash, cash equivalents and marketable securities were
Revenues: Revenues were
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative Expenses: General and administrative expenses were
Net Income: Net income was
FINANCIAL GUIDANCE
REGENXBIO expects its balance in cash, cash equivalents and marketable securities of
CONFERENCE CALL
In connection with this announcement, REGENXBIO will host a conference call and webcast at 8:00 a.m. ET today. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.REGENXBIO.com.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timing or likelihood of payments from AbbVie or Nippon Shinyaku, the monetization of any priority review voucher, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC) and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC's website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Zolgensma® and Itvisma® are registered trademarks of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.
CONTACTS:
Dana Cormack
Corporate Communications
Dcormack@regenxbio.com
George E. MacDougall
Investor Relations
IR@regenxbio.com
REGENXBIO INC. | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
(unaudited) | ||||||||
(in thousands) | ||||||||
June 30, 2026 | December 31, 2025 | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 36,487 | $ | 34,466 | ||||
Marketable securities | 69,030 | 195,604 | ||||||
Accounts receivable | 106,754 | 26,379 | ||||||
Prepaid expenses | 11,904 | 11,927 | ||||||
Restricted cash | 225 | — | ||||||
Other current assets | 11,757 | 12,905 | ||||||
Total current assets | 236,157 | 281,281 | ||||||
Marketable securities | — | 10,785 | ||||||
Accounts receivable | 435 | 2,312 | ||||||
Property and equipment, net | 98,452 | 104,855 | ||||||
Operating lease right-of-use assets | 43,867 | 47,156 | ||||||
Restricted cash | 1,805 | 2,030 | ||||||
Other assets | 5,902 | 4,613 | ||||||
Total assets | $ | 386,618 | $ | 453,032 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 15,546 | $ | 21,358 | ||||
Accrued expenses and other current liabilities | 23,073 | 38,390 | ||||||
Deferred revenue | 9,882 | 10,452 | ||||||
Operating lease liabilities | 7,355 | 8,286 | ||||||
Royalty monetization liabilities | 26,765 | 39,609 | ||||||
Total current liabilities | 82,621 | 118,095 | ||||||
Deferred revenue | 15,404 | 18,943 | ||||||
Operating lease liabilities | 61,596 | 65,215 | ||||||
Royalty monetization liabilities | 154,746 | 147,408 | ||||||
Other liabilities | 486 | 638 | ||||||
Total liabilities | 314,853 | 350,299 | ||||||
Stockholders' equity | ||||||||
Preferred stock; no shares issued and outstanding | — | — | ||||||
Common stock; 54,164 and 50,892 shares issued | 5 | 5 | ||||||
Additional paid-in capital | 1,266,004 | 1,229,442 | ||||||
Accumulated other comprehensive loss | (875) | (687) | ||||||
Accumulated deficit | (1,193,369) | (1,126,027) | ||||||
Total stockholders' equity | 71,765 | 102,733 | ||||||
Total liabilities and stockholders' equity | $ | 386,618 | $ | 453,032 | ||||
REGENXBIO INC. | ||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) | ||||||||||||||||
(unaudited) | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
Three Months | Six Months | |||||||||||||||
Ended June 30, | Ended June 30, | |||||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
Revenues | ||||||||||||||||
License and royalty revenue | $ | 103,841 | $ | 18,465 | $ | 108,931 | $ | 105,514 | ||||||||
Service revenue | 4,178 | 2,894 | 5,481 | 4,857 | ||||||||||||
Total revenues | 108,019 | 21,359 | 114,412 | 110,371 | ||||||||||||
Operating Expenses | ||||||||||||||||
Cost of license and royalty revenues | 1,042 | 5,209 | 12,116 | 8,645 | ||||||||||||
Research and development | 56,086 | 59,500 | 113,425 | 112,587 | ||||||||||||
General and administrative | 21,616 | 19,883 | 42,922 | 40,230 | ||||||||||||
Other operating expenses | 12 | 45 | 48 | 60 | ||||||||||||
Total operating expenses | 78,756 | 84,637 | 168,511 | 161,522 | ||||||||||||
Income (loss) from operations | 29,263 | (63,278) | (54,099) | (51,151) | ||||||||||||
Other Income (Expense) | ||||||||||||||||
Interest income from licensing | 17 | 21 | 33 | 46 | ||||||||||||
Investment income | 1,222 | 3,379 | 3,225 | 5,880 | ||||||||||||
Interest expense | (7,793) | (10,993) | (16,501) | (19,563) | ||||||||||||
Total other income (expense) | (6,554) | (7,593) | (13,243) | (13,637) | ||||||||||||
Net income (loss) | $ | 22,709 | $ | (70,871) | $ | (67,342) | $ | (64,788) | ||||||||
Other Comprehensive Income (Loss) | ||||||||||||||||
Unrealized gain (loss) on available-for-sale securities, net | (5) | 12 | (188) | (9) | ||||||||||||
Total other comprehensive income (loss) | (5) | 12 | (188) | (9) | ||||||||||||
Comprehensive income (loss) | $ | 22,704 | $ | (70,859) | $ | (67,530) | $ | (64,797) | ||||||||
Net income (loss) per share: | ||||||||||||||||
Basic | $ | 0.43 | $ | (1.38) | $ | (1.28) | $ | (1.26) | ||||||||
Diluted | $ | 0.43 | $ | (1.38) | $ | (1.28) | $ | (1.26) | ||||||||
Weighted-average common shares outstanding: | ||||||||||||||||
Basic | 52,820 | 51,483 | 52,625 | 51,423 | ||||||||||||
Diluted | 53,016 | 51,483 | 52,625 | 51,423 | ||||||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2026-financial-results-and-operational-highlights-302844662.html
SOURCE REGENXBIO Inc.